1. Plus! Choose from two comprehensive pre-conference workshops:
A: Oncology Imaging Endpoint Assessment | B: Surrogate Endpoints and Accelerated Drug Approval Pathways
C O N F E R E N C E P R E V I E W *
Life Sciences *This is preliminary conference information. Topics, agenda and speaker names are subject to change without notice.
November 2-3, 2015 • Philadelphia, PA
Validate Endpoints, Interpret QOL Scores and Incorporate Patient Preferences
to Satisfy Regulatory Requirements for Reliability and Validity
Oncology Endpoints &
QOL Assessments
Who Should Attend
You will benefit from attending this event if you are a manager, associate director, director
or vice president from a biotech, pharmaceutical, medical device company or academic
research institute with responsibilities or involvement in the following areas:
Oncology Heads • Program Leads • Medical Affairs • HEOR • PRO
Clinical Research/Outcomes • Data Management/Statistics
This conference will also benefit consultants, CROs, imaging and technology
vendors working with the above audience.
Although the FDA has long-time considered OS as the gold standard for oncology endpoints, there has been a
push for the inclusion of patient preferences and benefit-risk assessments, leading to the acceptance of surrogate
endpoints based on QOL measures.
CBI’s Oncology Endpoints and QOL Assessments provides insight into the rapidly changing field of oncology
clinical trials including case studies and perspectives surrounding endpoint selection, QOL interpretation and the
development of PRO measures to ensure validity and integrity of the trial to support regulatory approval.
Benchmark against leading oncology thought-leaders:
A Great Place to Meet Your Market!
Take advantage of the best opportunity to
meet potential clients face-to-face. Build
relationships while demonstrating thought
leadership and sharing expertise. For more
information on how to position your
company as a sponsor or exhibitor, contact:
Taylor Biggers
339-298-2108 | taylor.biggers@cbinet.com
Understand patient needs when designing clinical trials and assessing oncology endpoints in terms of disease,
treatment and impact of therapy
Develop patient reported outcome tools to identify benefit-risk assessments of treatments
Create strategies to validate endpoints without subjecting the immune system to toxicities in
immuno-oncology clinical trials
Obtain PRO label claims in oncology trials by creating system indexes
Ira Klein,
Medical Director,
Aetna
Scott Megaffin,
President,
Churchill
Pharmaceuticals, LLC
David Cella, Ph.D.,
Director,
Patient-Centered
Outcomes,
Institute of Public
Health for Medicine
Pablo Lapuerta, M.D.,
Executive Vice President
and Chief Medical
Officer, Lexicon
Pharmaceuticals
Featured Speakers: